Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, in partnership with Mayo Clinic researchers, presented new findings at Digestive Disease Week (DDW) ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.